Literature DB >> 20978517

Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.

Zhifei Wang1, Yan Leng, Li-Kai Tsai, Peter Leeds, De-Maw Chuang.   

Abstract

Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is known to protect against cerebral ischemia. The effects of VPA on blood-brain barrier (BBB) disruption were investigated in rats subjected to transient middle cerebral artery occlusion (MCAO). Postischemic VPA treatment remarkably attenuated MCAO-induced BBB disruption and brain edema. Meanwhile, VPA significantly reduced MCAO-induced elevation of matrix metalloproteinase-9 (MMP-9), degradation of tight junction proteins, and nuclear translocation of nuclear factor-κB (NF-κB). Sodium butyrate, another HDAC inhibitor, mimicked these effects of VPA. Our findings suggest that BBB protection by VPA involves HDAC inhibition-mediated suppression of NF-κB activation, MMP-9 induction, and tight junction degradation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978517      PMCID: PMC3049473          DOI: 10.1038/jcbfm.2010.195

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  15 in total

1.  Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.

Authors:  Anil Zechariah; Ayman ElAli; Dirk M Hermann
Journal:  Stroke       Date:  2010-04-01       Impact factor: 7.914

2.  Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia.

Authors:  M Asahi; X Wang; T Mori; T Sumii; J C Jung; M A Moskowitz; M E Fini; E H Lo
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

3.  Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.

Authors:  Yi Yang; Eduardo Y Estrada; Jeffrey F Thompson; Wenlan Liu; Gary A Rosenberg
Journal:  J Cereb Blood Flow Metab       Date:  2006-07-19       Impact factor: 6.200

4.  Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.

Authors:  Tong Cheng; Anthony L Petraglia; Zhang Li; Meenakshisundaram Thiyagarajan; Zhihui Zhong; Zhenhua Wu; Dong Liu; Sanjay B Maggirwar; Rashid Deane; José A Fernández; Barbra LaRue; John H Griffin; Michael Chopp; Berislav V Zlokovic
Journal:  Nat Med       Date:  2006-10-29       Impact factor: 53.440

Review 5.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

6.  Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo.

Authors:  Giuseppe Faraco; Maria Pittelli; Leonardo Cavone; Silvia Fossati; Marco Porcu; Paolo Mascagni; Gianluca Fossati; Flavio Moroni; Alberto Chiarugi
Journal:  Neurobiol Dis       Date:  2009-07-25       Impact factor: 5.996

Review 7.  Multiphasic roles for matrix metalloproteinases after stroke.

Authors:  Anna Rosell; Eng H Lo
Journal:  Curr Opin Pharmacol       Date:  2008-01-15       Impact factor: 5.547

8.  MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.

Authors:  Anna Rosell; Eloy Cuadrado; Arantxa Ortega-Aznar; Mar Hernández-Guillamon; Eng H Lo; Joan Montaner
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

9.  Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats.

Authors:  Kyung-Pil Park; Anna Rosell; Christian Foerch; Changhong Xing; Woo Jean Kim; Seoul Lee; Ghislain Opdenakker; Karen L Furie; Eng H Lo
Journal:  Stroke       Date:  2009-06-25       Impact factor: 7.914

10.  Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.

Authors:  Taura L Barr; Lawrence L Latour; Kyung-Yul Lee; Timothy J Schaewe; Marie Luby; George S Chang; Ziad El-Zammar; Shaista Alam; John M Hallenbeck; Chelsea S Kidwell; Steven Warach
Journal:  Stroke       Date:  2009-12-24       Impact factor: 7.914

View more
  107 in total

1.  Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model.

Authors:  Li-Kai Tsai; Zhifei Wang; Jeeva Munasinghe; Yan Leng; Peter Leeds; De-Maw Chuang
Journal:  Stroke       Date:  2011-08-11       Impact factor: 7.914

Review 2.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

3.  Apocynum venetum leaf extract attenuates disruption of the blood-brain barrier and upregulation of matrix metalloproteinase-9/-2 in a rat model of cerebral ischemia-reperfusion injury.

Authors:  Jun Xiang; Rui Lan; Yu-Ping Tang; Yi-Ping Chen; Ding-Fang Cai
Journal:  Neurochem Res       Date:  2012-05-17       Impact factor: 3.996

Review 4.  Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.

Authors:  Philip Lee; Ben Murphy; Rickey Miller; Vivek Menon; Naren L Banik; Pierre Giglio; Scott M Lindhorst; Abhay K Varma; William A Vandergrift; Sunil J Patel; Arabinda Das
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

Review 5.  Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury.

Authors:  Selva Baltan; Richard S Morrison; Sean P Murphy
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 6.  Epigenetic mechanisms in stroke and epilepsy.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Neuropsychopharmacology       Date:  2012-08-15       Impact factor: 7.853

7.  Valproate and sodium butyrate attenuate manganese-decreased locomotor activity and astrocytic glutamate transporters expression in mice.

Authors:  James Johnson; Edward Alain B Pajarillo; Equar Taka; Romonia Reams; Deok-Soo Son; Michael Aschner; Eunsook Lee
Journal:  Neurotoxicology       Date:  2017-06-10       Impact factor: 4.294

Review 8.  The emerging field of epigenetics in neurodegeneration and neuroprotection.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

9.  MiR-539 Targets MMP-9 to Regulate the Permeability of Blood-Brain Barrier in Ischemia/Reperfusion Injury of Brain.

Authors:  Feng Fan; Jiao Yang; Yuanjie Xu; Sheng Guan
Journal:  Neurochem Res       Date:  2018-10-01       Impact factor: 3.996

10.  HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation.

Authors:  Hyeon Ju Kim; De-Maw Chuang
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.